

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE FOURTH QUARTER ENDED 31 DECEMBER 2022**

	Note	Individual quarter		Cumulative quarter	
		Current year quarter	Preceding year quarter	Current year-to-date	Preceding year-to-date
		31/12/2022 RM'000	31/12/2021 RM'000	31/12/2022 RM'000	31/12/2021 RM'000
<b>Revenue</b>		53,719	49,022	198,152	169,431
Cost of sales		(40,973)	(34,681)	(144,295)	(118,253)
<b>Gross profit</b>		12,746	14,341	53,857	51,178
Other operating income		682	624	1,700	1,798
Distribution costs		(2,929)	(166)	(12,194)	(9,549)
Administration expenses		(5,847)	(8,955)	(22,992)	(24,544)
Finance costs		(131)	(253)	(1,323)	(1,278)
<b>Profit before tax</b>		4,521	5,591	19,048	17,605
Tax expense	B5	(688)	(2,079)	(4,411)	(5,086)
<b>Profit for the financial period</b>		3,833	3,512	14,637	12,519
Other comprehensive income, net of tax		-	-	-	-
<b>Total comprehensive income</b>		3,833	3,512	14,637	12,519
<b>Profit attributable to:</b>					
Owners of the parent		3,059	3,137	12,738	11,268
Non-controlling interests		774	375	1,899	1,251
		3,833	3,512	14,637	12,519
<b>Total comprehensive income attributable to:</b>					
Owners of the parent		3,059	3,137	12,738	11,268
Non-controlling interests		774	375	1,899	1,251
		3,833	3,512	14,637	12,519
<b>Earnings per ordinary share attributable to owners of the parent:</b>					
- Basic (sen)	B15	1.38	1.56	5.86	5.61
- Diluted (sen)	B15	1.02	1.12	4.28	4.01

The Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2021 and the accompanying explanatory notes attached to these interim financial statements.

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2022**

	Note	As at 31/12/2022 RM'000	Audited As at 31/12/2021 RM'000
<b>Non-current asset</b>			
Property, plant and equipment		77,601	78,523
Right-of-use assets		10,839	11,141
Investment property		5,525	5,567
Biological assets		3,600	3,367
Goodwill		3,941	3,941
Other investment	B9	70	24
		<u>101,576</u>	<u>102,563</u>
<b>Current assets</b>			
Inventories		60,831	33,246
Trade and other receivables		37,930	38,578
Current tax assets		454	799
Cash and bank balances and short term funds		18,644	20,620
		<u>117,859</u>	<u>93,243</u>
<b>Total assets</b>		<u>219,435</u>	<u>195,806</u>
<b>Equity</b>			
Share capital		117,272	103,618
Reorganisation debit balance	B17	(59,489)	(59,489)
Exchange translation reserve		3	-
Retained earnings		95,546	87,236
<b>Total attributable to owners of the parent</b>		<u>153,332</u>	<u>131,365</u>
Non-controlling interests		9,687	7,788
<b>Total equity</b>		<u>163,019</u>	<u>139,153</u>
<b>Non-current liabilities</b>			
Borrowings	B10	21,822	25,698
Lease liabilities		260	177
Deferred tax liabilities		1,704	1,918
Deferred income		86	400
		<u>23,872</u>	<u>28,193</u>
<b>Current Liabilities</b>			
Trade and other payables		24,569	19,835
Borrowings	B10	6,893	7,087
Lease liabilities		260	315
Deferred income		14	14
Current tax liabilities		808	1,209
		<u>32,544</u>	<u>28,460</u>
<b>Total liabilities</b>		<u>56,416</u>	<u>56,653</u>
<b>Total equity and liabilities</b>		<u>219,435</u>	<u>195,806</u>

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT  
31 DECEMBER 2022 (CONTINUED)**

	<b>Note</b>	<b>As at 31/12/2022</b>	<b>Audited As at 31/12/2021</b>
<b>Net assets per share attributable to owners of the parent (RM)</b>	B16	0.69	0.65

The Unaudited Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2021 and the accompanying explanatory notes attached to these interim financial statements.

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FOURTH QUARTER ENDED 31 DECEMBER 2022**

	<----- Attributable to owners of the parent ----->						Non-controlling interest RM'000	Total equity RM'000
	<----- Non-distributable ----->			Distributable		Total attributable to owners of the parent RM'000		
	Share capital RM'000	Exchange translation reserve RM'000	Reorganisation debit balance RM'000	Retained earnings RM'000				
<b>Balance as at 1 January 2022</b>	103,618	-	(59,489)	87,236	131,365	7,788	139,153	
Profit for the financial year	-	-	-	12,738	12,738	1,899	14,637	
Other comprehensive income, net of tax	-	3	-	(3)	-	-	-	
Total comprehensive income	-	3	-	12,735	12,738	1,899	14,637	
Transactions with owners:								
Issuance of ordinary shares - private placement	13,458	-	-	-	13,458	-	13,458	
Issuance of ordinary shares - exercise of warrants	196	-	-	-	196	-	196	
Dividends paid	-	-	-	(4,425)	(4,425)	-	(4,425)	
Total transactions with owners	13,654	-	-	(4,425)	9,229	-	9,229	
<b>Balance as at 31 December 2022</b>	117,272	3	(59,489)	95,546	153,332	9,687	163,019	
<b>Balance as at 1 January 2021</b>	103,618	-	(59,489)	79,985	124,114	6,537	130,651	
Profit for the financial year	-	-	-	11,268	11,268	1,251	12,519	
Other comprehensive income, net of tax	-	-	-	-	-	-	-	
Total comprehensive income	-	-	-	11,268	11,268	1,251	12,519	
Transactions with owners:								
Dividends paid	-	-	-	(4,017)	(4,017)	-	(4,017)	
Total transactions with owners	-	-	-	(4,017)	(4,017)	-	(4,017)	
<b>Balance as at 31 December 2021</b>	103,618	-	(59,489)	87,236	131,365	7,788	139,153	

The Unaudited Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2021 and the accompanying explanatory notes attached to these interim financial statements.

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FOURTH QUARTER ENDED 31 DECEMBER 2022**

	<b>Current year- to-date 31/12/2022 RM'000</b>	<b>Preceding year-to-date 31/12/2021 RM'000</b>
<b>Cash flows from operating activities</b>		
Profit before tax	19,048	17,605
Adjustments for:		
Depreciation	3,754	3,607
Inventories written off	1,045	809
Inventories written (back)/down	(1,187)	590
Impairment losses on trade receivables	308	264
Fair value changes on other investment	4	7
Interest expense	1,323	1,278
Loss on disposal of biological assets	36	161
Fair value changes on biological assets	(409)	(560)
Interest income	(140)	(175)
Gain on disposal of property, plant and equipment	-	(261)
Gain on disposal of right-of-use asset	-	(115)
Property, plant and equipment written off	-	102
Unrealised gain on foreign currency exchange	(177)	(413)
Operating profit before working capital changes	<u>23,605</u>	<u>22,899</u>
Changes in working capital:		
Inventories	(27,444)	(4,013)
Trade and other receivables	340	(5,672)
Trade and other payables	<u>4,595</u>	<u>2,670</u>
Cash generated from operations	1,096	15,884
Tax paid	<u>(4,680)</u>	<u>(4,213)</u>
Net cash (used in)/from operating activities	<u>(3,584)</u>	<u>11,671</u>
<b>Cash flows from investing activities</b>		
Purchase of property, plant and equipment	(2,262)	(9,307)
Interest received	140	175
Acquisition of quoted shares	(50)	-
Purchase of biological assets	-	(835)
Proceeds from disposal of property, plant and equipment		1,058
Proceeds from disposal of right-of-use asset		1,026
Proceeds from disposal of biological assets	140	84
Receipt of government grant		<u>417</u>
Net cash used in investing activities	<u>(2,032)</u>	<u>(7,382)</u>
<b>Cash flows from financing activities</b>		
Net repayment of borrowings	(4,070)	(4,521)
Interest paid	(1,309)	(1,249)
Dividend paid	(4,425)	(2,009)
Payment of lease liabilities	(210)	(366)
Proceeds from issuance of shares	<u>13,654</u>	<u>-</u>
Net cash from/(used in) financing activities	<u>3,640</u>	<u>(8,145)</u>

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE  
FOURTH QUARTER ENDED 31 DECEMBER 2022 (CONTINUED)**

	<b>Current year- to-date 31/12/2022 RM'000</b>	<b>Preceding year-to-date 31/12/2021 RM'000</b>
Net decrease in cash and cash equivalents	(1,976)	(3,856)
Cash and cash equivalents at beginning of financial year	<u>20,620</u>	<u>24,476</u>
Cash and cash equivalents at end of financial year	<u>18,644</u>	<u>20,620</u>

The Unaudited Condensed Consolidated Statement of Cash Flows should be read in conjunction with the audited financial statements for the financial year ended 31 December 2021 and the accompanying explanatory notes attached to these interim financial statements.

**A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS (“MFRS”) 134: INTERIM FINANCIAL REPORTING**

**A1. Basis of preparation**

The unaudited interim financial statements have been prepared in accordance with the requirements of MFRS 134 *Interim Financial Reporting* and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

These explanatory notes attached to the interim financial statements provide an explanation of events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 December 2021 and should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 December 2021.

**A2. Significant accounting policies**

The significant accounting policies and methods of computation adopted for the interim financial statements are consistent with those adopted for the audited financial statements of the Group for the financial year ended 31 December 2021, except for the adoption of the following amendments to MFRSs during the financial year:

- Annual Improvements to MFRS Standards 2018 - 2020
- Amendments to MFRS 3 *Reference to the Conceptual Framework*
- Amendments to MFRS 116 *Property, Plant and Equipment - Proceeds before Intended Use*
- Amendments to MFRS 137 *Onerous Contracts - Cost of Fulfilling a Contract*

The adoption of the above amendments had no significant impact to the financial statements of the Group.

**A3. Auditors’ report**

There was no qualification to the audited financial statements of the Company and its subsidiaries for the financial year ended 31 December 2021.

**A4. Seasonal or cyclical factors**

The business operations of the Group were not materially affected by any seasonal and cyclical factors during the current quarter and financial year-to-date under review.

**A5. Unusual items affecting assets, liabilities, equity, net income or cash flows**

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group for the current quarter and financial year-to-date under review.

**A6. Changes in estimates**

There were no changes in estimates that have a material effect in the current quarter and financial year-to-date under review.

**A7. Debt and equity securities**

On 8 February 2022, Public Investment Bank Berhad had on behalf of the Board of Directors of the Company, announced that the Company proposes to undertake a proposed private placement of up to 28,120,300 new ordinary shares in the Company (“Placement Share(s)”), representing up to 10% of the enlarged number of issued shares in the Company (“Proposed Private Placement”).

The Company further announced on 14 February 2022 that Bursa Malaysia Securities Berhad (“Bursa Securities”) had, via its letter dated 14 February 2022, approved the listing and quotation of up to 28,120,300 Placement Shares to be issued pursuant to the Proposed Private Placement on the Main Market of Bursa Securities, subject to the conditions set out in Bursa Securities’ letter.

On 11 March 2022, the Company announced that the private placement of up to 28,120,300 new shares in the Company representing up to 10% of the enlarged number of issued shares of the Company (“Private Placement”) has been fixed at RM0.67 per Placement Share and will comprise up to 20,086,000 Placement Shares.

On 14 March 2022, the Company announced that the Private Placement has been completed following the listing of and quotation for 20,086,000 Placement Shares on the Main Market of Bursa Securities with effect from 9.00 a.m. on 14 March 2022. Pursuant to the Private Placement, the issued shares of the Company increased from 200,860,000 ordinary shares to 220,946,000 ordinary shares.

On 5 April 2022, the issued shares of the Company further increased from 220,946,000 ordinary shares to 221,226,000 ordinary shares pursuant to the issuance of 280,000 new ordinary shares arising from the exercise of 280,000 warrants by a warrant holder.

Save for the above, there were no other issuance, cancellation, repurchase, resale or repayment of debt and equity securities for the current quarter and financial year-to-date under review.

**A8. Dividend**

There was no dividend paid during the current quarter under review.

On 24 December 2021, the Board of Directors declared an interim single tier dividend of 1.0 sen per ordinary share totalling RM2.01 million in respect of the financial year ended 31 December 2021. The dividend had been accounted for in equity as an appropriation of retained earnings in the financial year ended 31 December 2021 and was paid on 25 January 2022 to shareholders registered at the close of business on 13 January 2022.

A final single tier dividend of 1.0 sen per ordinary share in respect of the financial year ended 31 December 2021 was approved by shareholders at the Company’s Annual General Meeting on 14 June 2022. The dividend was paid on 15 July 2022 and had been accounted for in equity as an appropriation of retained earnings in the financial year ended 31 December 2022.

**A9. Segmental information**

The Group’s operating segments are animal health products and equipment, food ingredients and others. These operating segments are required to be organised and managed separately according to the nature of products and services as well as specific expertise which require different business and marketing strategies. The segmental results are as follows:

	Individual quarter		Cumulative quarter	
	Current year quarter	Preceding year quarter	Current year-to-date	Preceding year-to-date
	31/12/2022 RM'000	31/12/2021 RM'000	31/12/2022 RM'000	31/12/2021 RM'000
<b>Revenue</b>				
Animal health products and equipment	38,613	38,406	151,429	133,816
Food ingredients	9,258	7,684	35,343	27,242
Others	5,848	2,932	11,380	8,373
	<u>53,719</u>	<u>49,022</u>	<u>198,152</u>	<u>169,431</u>
<b>Profit before tax</b>				
Animal health products and equipment	3,861	4,461	16,790	13,694
Food ingredients	274	1,338	2,434	3,221
Others	386	(208)	(176)	690
	<u>4,521</u>	<u>5,591</u>	<u>19,048</u>	<u>17,605</u>

**A10. Property, plant and equipment**

(i) Acquisitions and disposals

There were no material acquisitions and disposals during the current quarter and financial year-to-date under review.

(ii) Impairment losses

There were no material impairment losses during the current quarter and financial year-to-date under review.

(iii) Valuation

The Group has not carried out any valuation on its property, plant and equipment during the current quarter and financial year-to-date under review.

**A11. Material events subsequent to the end of the quarter**

There were no material events subsequent to the end of the current quarter that have not been reflected in this interim financial report.

**A12. Changes in the composition of the Group**

There were no changes in the composition of the Group during the current quarter and financial year-to-date under review.

**A13. Contingent liabilities and contingent assets**

There were no contingent liabilities or contingent assets as at the date of this report.

**A14. Capital commitments**

The capital commitments of the Group as at the end of the quarter under review were as follows:

	RM'000
Approved and contracted for:	
- Machineries and equipment	1,110
- Milk processing plant	4,626
	<u>5,736</u>

**A15. Significant related party transactions**

The related party transactions during the current quarter and financial year-to-date under review are as follows:

	Individual quarter		Cumulative quarter	
	Current year quarter 31/12/2022 RM'000	Preceding year quarter 31/12/2021 RM'000	Current year-to-date 31/12/2022 RM'000	Preceding year-to-date 31/12/2021 RM'000
Nor Livestock Farm Sdn Bhd (“NLF”) purchases feed from Nor Lazuli Nutrition (“NLN”)	-	99	-	785
NLF purchases milk replacer from NLN	-	2	-	11
NLN purchases rice straw from NLF	-	3	-	33
One Lazuli Sdn Bhd (“OLSB”) purchases feed from NLN	-	-	-	20
OLSB provides transportation services to NLN	-	2	-	14
NLF purchases anti-inflammatory medication, antibiotics, anti-parasitics and dairy milk machine parts from OLSB	-	7	-	124
NLN rents an office space from OLSB	-	1	-	10
NLF rents an office space from OLSB	-	-	-	2
NLF rents a farm land from Raja Mariam Binti Raja Rustam Shahrome (“RMRRS”), Dr Mai Lam @ Rosli Mai Lam (“ML”) and Melissa Aini Mai (“MAM”)	8	8	30	30
NLN rents a factory building from RMRRS, ML and MAM	8	8	30	30
OLSB rents an office space from RMRRS	45	45	180	180

**B. ADDITIONAL INFORMATION REQUIRED BY THE MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD**

**B1. Review of performance**

The Group recorded revenue of approximately RM53.72 million for the current quarter, an increase of approximately RM4.70 million compared to the revenue of approximately RM49.02 million in the preceding year's corresponding quarter. Revenue from animal health products and equipment increased by approximately RM0.20 million from approximately RM38.41 million in the preceding year's corresponding quarter to approximately RM38.61 million in the current quarter. Revenue from food ingredients increased by approximately RM1.58 million from approximately RM7.68 million in the preceding year's corresponding quarter to approximately RM9.26 million in the current quarter. Revenue from dairy business, which is categorised under others, increased by approximately RM3.14 million from approximately RM1.71 million in the preceding year's corresponding quarter to approximately RM4.85 million in the current quarter.

Despite the increase in revenue, the Group's profit before tax for the current quarter of approximately RM4.52 million was approximately RM1.07 million lower compared to the profit before tax of approximately RM5.59 million reported for the preceding year's corresponding quarter. This was mainly due to the decrease in gross profit of approximately RM1.60 million as a result of higher materials costs.

For the financial year-to-date under review, the Group recorded revenue of approximately RM198.15 million, an increase of approximately RM28.72 million compared to the revenue of approximately RM169.43 million in the preceding year. Revenue from animal health products and equipment increased by approximately RM17.61 million from approximately RM133.82 million in the preceding year to approximately RM151.43 million in the current year. Revenue from food ingredients increased by approximately RM8.10 million from approximately RM27.24 million in the preceding year to approximately RM35.34 million in the current year. Revenue from dairy business, which is categorised under others, increased by approximately RM2.84 million from approximately RM4.56 million in the preceding year to approximately RM7.40 million in the current year.

Consistent with the increase in revenue, the Group's profit before tax for the financial year under review of approximately RM19.05 million was approximately RM1.44 million higher compared to the profit before tax of approximately RM17.61 million reported for the preceding year.

**B2. Material changes in the quarterly results compared to the immediate preceding quarter**

The Group's revenue of approximately RM53.72 million for the current quarter was approximately RM2.34 million higher compared to the revenue of approximately RM51.38 million reported for the preceding quarter. The increase in revenue is mainly due to higher revenue from dairy business, which is categorised under others, which increased by approximately RM4.56 million from approximately RM0.29 million in the preceding quarter to approximately RM4.85 million in the current quarter. Revenue from food ingredients also increased by approximately RM1.34 million from approximately RM7.92 million in the preceding quarter to approximately RM9.26 million in the current quarter. However, the increases were offset by decrease in revenue from animal health products and equipment of approximately RM3.77 million from approximately RM42.38 million in the preceding quarter to approximately RM38.61 million in the current quarter.

Despite the increase in revenue, the Group's profit before tax for the current quarter of approximately RM4.52 million was approximately RM0.66 million lower compared to the profit before tax of approximately RM5.18 million reported for the preceding quarter. This

was mainly due to the decrease in gross profit of approximately RM1.96 million as a result of higher materials costs.

**B3. Prospects**

The continued expansion of our operations through our future plans would provide a platform to grow and sustain our business. The Group will continue to focus on strengthening its production capabilities, product competitiveness and market position, while constantly seeking ways to mitigate the risks associated with its business. The Group will also continue to improve its internal controls and processes based on prudent management practices. In addition to improving on current operations, the Group is vigilant in identifying new business opportunities that has the potential for continuous growth and expansion.

In line with the projected growth of the Malaysian economy, the livestock industry is also anticipated to grow due to the corresponding growing Malaysian population resulting in the demand for meat as a source of protein to soar. The estimated increase in livestock in Malaysia is expected to result in correlating increase in demand for animal pharmaceutical and veterinary products, including animal feed to meet the rising needs. This is expected to augur well for the Group to ride on the growth trajectory in line with the government's endeavour to develop a sustainable livestock industry in the country for national food security.

Based on the above, the Board is cautiously optimistic on the prospects and outlook of the Group. However, the Group will undertake a prudent approach in managing its business operations and aims to improve its efficiency and resilience in order to mitigate any risk that the Group may encounter moving forward.

**B4. Profit forecast**

The Group has not issued any profit forecast in any form of public documentation and announcement.

**B5. Tax expense**

	Individual quarter		Cumulative quarter	
	Current year quarter 31/12/2022 RM'000	Preceding year quarter 31/12/2021 RM'000	Current year-to-date 31/12/2022 RM'000	Preceding year-to-date 31/12/2021 RM'000
<b>Current tax</b>				
Current year	597	732	4,449	3,670
Under/(over) provision in prior years	305	(135)	176	(66)
	<u>902</u>	<u>597</u>	<u>4,625</u>	<u>3,604</u>
<b>Deferred tax</b>				
Origination of temporary differences	248	1,426	248	1,426
(Over)/under provision in prior years	(462)	56	(462)	56
	<u>(214)</u>	<u>1,482</u>	<u>(214)</u>	<u>1,482</u>
	<u>688</u>	<u>2,079</u>	<u>4,411</u>	<u>5,086</u>

The effective tax rates of the Group for the current quarter and financial year-to-date of 15.22% and 23.16% respectively were lower than the statutory tax rate of 24.00% mainly due to the reversal of over provision of deferred tax in prior years.

**B6. Notes to the Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income**

	Individual quarter		Cumulative quarter	
	Current year quarter	Preceding year quarter	Current year-to-date	Preceding year-to-date
	31/12/2022	31/12/2021	31/12/2022	31/12/2021
	RM'000	RM'000	RM'000	RM'000
<b>Profit before tax is arrived at after charging / (crediting):</b>				
Depreciation	964	1,191	3,754	3,607
Inventories written off	677	285	1,045	809
Inventories written (back)/down	(1,494)	341	(1,187)	590
Impairment losses/(reversal) on trade receivables	160	(96)	308	264
Fair value changes on other investment	(5)	6	4	7
Interest expense	131	253	1,323	1,278
Loss on disposal of biological assets	6	14	36	161
Fair value changes on biological assets	(81)	(137)	(409)	(560)
Interest income	(50)	(42)	(140)	(175)
(Gain)/loss on foreign currency exchange	(576)	(288)	(1,092)	518

Save for the above, the other items as required under Appendix 9B Part A (16) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad are not applicable.

**B7. Status of corporate proposals**

There is no corporate proposal announced but not completed as at the date of this report.

**B8. Utilisation of proceeds**

The status of utilisation of proceeds of approximately RM13.46 million from the Company's Private Placement of 20,086,000 new ordinary shares at RM0.67 each as at the end of the quarter under review is as follows:

Details of the utilisation of proceeds	Proposed utilisation	Actual utilisation	Deviation	Balance unutilised	Estimated timeframe for utilisation
	RM'000	RM'000	RM'000	RM'000	
Establishment of a milk processing plant	7,500	(2,704)	-	4,796	Within 36 months
Marketing expenses	2,500	-	-	2,500	Within 36 months
Working capital	3,008	-	42 <sup>(1)</sup>	3,050	Within 12 months
Estimated expenses for the Private Placement	450	(408)	(42) <sup>(1)</sup>	-	Within 1 month
<b>Total</b>	<b>13,458</b>	<b>(3,112)</b>	<b>-</b>	<b>10,346</b>	

Note:

(1) The actual expenses incurred for the Private Placement were less than the estimated expenses by approximately RM0.04 million due mainly to lower than expected incidental charges incurred in conjunction with the Private Placement. The surplus of funds for the payment of expenses for the Private Placement were adjusted to the amount allocated for working capital.

The utilisation of the proceeds as disclosed above should be read in conjunction with the Company's announcement dated 8 February 2022 and 11 February 2022.

**B9. Other investment**

	As at 31/12/2022 RM'000	As at 31/12/2021 RM'000
<b>Financial asset at fair value through profit or loss</b>		
Quoted shares in Malaysia	100	50
Less: Impairment loss	(30)	(26)
	<u>70</u>	<u>24</u>

**B10. Borrowings**

	As at 31/12/2022 RM'000	As at 31/12/2021 RM'000
<b>Non-current liabilities (secured)</b>		
Term loans	<u>21,822</u>	<u>25,698</u>
<b>Current liabilities (secured)</b>		
Bank overdrafts	1,520	2,508
Revolving credits	3,000	-
Term loans	<u>2,373</u>	<u>4,579</u>
	<u>6,893</u>	<u>7,087</u>
<b>Total borrowings</b>	<u>28,715</u>	<u>32,785</u>

All borrowings are denominated in Ringgit Malaysia.

**B11. Material litigation**

There was no litigation which has a material effect on the financial position of the Group and the Board was not aware of any proceedings pending or of any fact likely to give rise to any proceedings as at the date of this report.

**B12. Dividend**

On 15 December 2022, the Board of Directors declared an interim single tier dividend of 1.0 sen per ordinary share totalling RM2.21 million in respect of the financial year ended 31 December 2022, which had been paid on 16 January 2023 to shareholders registered at the close of business on 3 January 2023. The dividend had been accounted for in equity as an appropriation of retained earnings in the financial year ended 31 December 2022.

**B13. Derivative financial instruments**

The Group does not have any derivative financial instruments as at the end of the current quarter.

**B14. Gains/losses arising from fair value changes of financial liabilities**

There were no material gains or losses arising from fair value changes of financial liabilities during the current quarter and financial year-to-date under review.

**B15. Earnings per share**

	Individual quarter		Cumulative quarter	
	Current year quarter 31/12/2022	Preceding year quarter 31/12/2021	Current year-to-date 31/12/2022	Preceding year-to-date 31/12/2021
Profit attributable to owners of the parent (RM'000)	3,059	3,137	12,738	11,268
Weighted average number of ordinary shares in issue ( '000)	221,226	200,860	217,412	200,860
Shares under warrant deemed to have been issued for no consideration ( '000)	80,064	80,344	80,064	80,344
Weighted average number of ordinary shares for computing diluted earnings per share ( '000)	301,290	281,204	297,476	281,204
Earnings per share				
- Basic (sen)	1.38	1.56	5.86	5.61
- Diluted (sen)	1.02	1.12	4.28	4.01

**B16. Net assets per share**

Net assets per share attributable to owners of the parent is arrived at by dividing the total equity attributable to owners of the parent at the end of the financial period by the number of ordinary shares in issue at the end of the financial period.

	<b>As at 31/12/2022</b>	<b>As at 31/12/2021</b>
Total equity attributable to owners of the parent (RM'000)	<u>153,332</u>	<u>131,365</u>
Number of ordinary shares in issue ('000)	<u>221,226</u>	<u>200,860</u>
Net assets per share attributable to owners of the parent (RM)	<u><u>0.69</u></u>	<u><u>0.65</u></u>

**B17. Reorganisation debit balance**

The reorganisation debit balance arose from the acquisition of RMM on 28 September 2016 based on the difference between the share capital issued by the Company and the share capital issued by RMM amounting to approximately RM59.49 million.